Anatomic Pathology Testing Market by Test Type (Digital Pathology, Hematoxylin And Eosin Staining, Immunohistochemistry), Sample Type (Cytology Samples, Frozen Sections, Tissue Biopsy), Application, End User - Global Forecast 2025-2032
Description
The Anatomic Pathology Testing Market was valued at USD 45.03 billion in 2024 and is projected to grow to USD 47.92 billion in 2025, with a CAGR of 6.58%, reaching USD 75.01 billion by 2032.
A comprehensive orientation to the evolving clinical, technological, and operational forces redefining anatomic pathology practice for decision-makers
Anatomic pathology stands at a crossroads of technological innovation, clinical demand, and operational transformation. This executive summary synthesizes the most salient developments shaping diagnostic practice, laboratory modernization, and research applications, drawing a line from laboratory bench processes through computational interpretation to clinical decision-making. It is intended to orient senior leaders, procurement teams, and clinical directors to practical implications and strategic opportunities that emerge as anatomic pathology adapts to evolving demands.
The following analysis emphasizes changes in diagnostic workflows, the integration of image analysis and molecular modalities, and the shifting relationships among providers, payers, and technology vendors. By emphasizing interoperability, regulatory alignment, and workforce dynamics, the narrative frames how institutions can translate technical advances into measurable improvements in diagnostic accuracy, turnaround times, and downstream patient management pathways. Alongside these themes, the summary highlights actionable considerations for capital planning, vendor selection, and internal capability building, providing a coherent foundation for strategic decision-making in the current clinical and commercial environment.
How converging advances in imaging, immunochemistry, and molecular diagnostics are reshaping diagnostic pathways, workflows, and laboratory partnerships
The anatomic pathology landscape is experiencing transformative shifts driven by digital enablement, expanding molecular diagnostics, and cross-disciplinary collaboration. Digital pathology platforms are moving beyond static image capture toward integrated systems that combine high-resolution slide scanners with advanced image analysis software, enabling pathologists to scale review workflows, support remote consultations, and standardize quantitation across cases. At the same time, immunohistochemistry remains fundamental, with monoclonal and polyclonal antibody reagent development improving specificity for biomarkers that inform therapeutic choices.
Concurrently, molecular pathology modalities such as fluorescence in situ hybridization, next-generation sequencing, and polymerase chain reaction are increasingly embedded into diagnostic algorithms, driving richer phenotypic and genotypic characterization of disease. Special staining techniques, including periodic acid–Schiff, silver, and trichrome stains, continue to provide critical morphological context that complements molecular readouts. These trends are occurring alongside workforce and workflow innovations, including centralized testing networks and partnerships between diagnostic laboratories and research institutes, which together are accelerating the translation of new assays into routine practice. As a result, institutions that can harmonize digital, immunohistochemical, and molecular domains are positioned to deliver more precise, reproducible, and clinically actionable pathology services.
The ripple effects of tariff policy shifts on supply stability, procurement strategies, and operational continuity in anatomic pathology settings
In 2025, changes to tariff policy in the United States have had a cumulative influence on supply chain dynamics and procurement decisions across anatomic pathology providers. Import tariffs and related customs adjustments have increased the cost sensitivity of capital equipment purchases such as slide scanners and ancillary hardware, while also affecting the landed cost of reagents and consumables that laboratories rely on for routine staining, immunohistochemistry, and molecular assays. These shifts have encouraged procurement teams to reevaluate sourcing strategies and to place greater emphasis on supplier diversification, local inventory buffering, and contractual protections against future tariff volatility.
Practically speaking, laboratories and research institutes have responded by negotiating longer-term supply contracts, seeking multi-source vendor relationships, and accelerating adoption of instrument-agnostic assays where possible. In parallel, some organizations have explored near-shoring or partnering with regional distributors to mitigate delivery lead times and customs complexity. Because equipment maintenance, validation, and regulatory compliance are critical, institutions must weigh the tradeoffs between short-term cost savings and long-term service reliability. Overall, tariff-related pressures have reinforced the importance of supply chain resilience, strategic stock management, and contractual clarity with vendors to sustain uninterrupted diagnostic operations and protect patient care continuity.
How multidimensional segmentation across test types, sample classes, applications, and end users informs targeted product development and deployment strategies
Segmentation insights reveal differentiated value drivers across test types, sample types, applications, and end users that collectively inform deployment and commercialization strategies. When considering test-type distinctions, digital pathology encompasses both image analysis software and slide scanners, each requiring distinct validation pathways and integration into laboratory information systems, whereas hematoxylin and eosin staining and special staining modalities such as periodic acid–Schiff, silver, and trichrome stains continue to underpin morphological assessment and support downstream ancillary testing. Immunohistochemistry divides into monoclonal antibody and polyclonal antibody reagents, with monoclonal formats often favored for standardized biomarker quantitation and polyclonal reagents retained for certain diagnostic contexts where broader antigen recognition is beneficial. Molecular pathology modalities span fluorescence in situ hybridization, next-generation sequencing, and polymerase chain reaction, collectively enabling diagnostic, prognostic, and predictive insights that complement histomorphology.
Turning to sample type, cytology samples, frozen sections, and tissue biopsy each pose differing pre-analytical and processing challenges that affect assay selection and workflow design; frozen sections demand rapid turnaround and robust intraoperative coordination, whereas tissue biopsy and cytology preparations enable a wider array of ancillary molecular and immunohistochemical testing. Application areas-genetic disorders, infectious diseases, and oncology-are further nuanced by sub-categories: genetic disorder testing differentiates between chromosomal and single-gene analyses; infectious disease testing separates bacterial from viral diagnostic approaches; and oncology applications prioritize organ-specific pathways such as breast, lung, and prostate cancer, which in turn shape marker panels and reflex testing strategies. Finally, end-user segmentation across diagnostic laboratories, hospitals, and research institutes underscores distinct procurement behaviors, validation requirements, and expectations for service levels. Diagnostic laboratories often prioritize throughput and assay standardization, hospitals emphasize integration with clinical pathways and turnaround, and research institutes value flexibility for novel assay development and exploratory biomarker evaluation. Together, these segmentation layers form a matrix that should guide product development, regulatory planning, and go-to-market tactics for stakeholders operating in anatomic pathology.
Regional adoption patterns and regulatory ecosystems that shape digital and molecular diagnostic deployment across the Americas, EMEA, and Asia-Pacific
Regional dynamics exert a strong influence on technology adoption, regulatory pathways, and partnership models across the anatomic pathology ecosystem. In the Americas, emphasis on consolidation among diagnostic providers and integrated delivery networks has driven investments in digital pathology and molecular testing infrastructure that supports centralized reference testing and telepathology services. This environment also fosters collaborations between hospitals and diagnostic laboratories to reduce turnaround times and support precision oncology programs.
In Europe, the Middle East & Africa, regulatory harmonization efforts, varying reimbursement landscapes, and a mix of centralized and decentralized laboratory networks create differentiated adoption patterns for advanced imaging and molecular assays. Regulatory alignment and cross-border collaborations are enabling broader deployment of validated digital workflows, while regional centers of excellence continue to drive training and best-practice dissemination. In the Asia-Pacific region, rapid capacity expansion, strong government-led initiatives to bolster diagnostic capability, and investments in local manufacturing and distribution networks are accelerating uptake of slide scanners, image analysis tools, and molecular platforms. Across all regions, local workforce capacity, reimbursement frameworks, and public health priorities modulate the pace and pattern of adoption, underlining the need for regionally tailored commercial and implementation strategies that respect regulatory and operational realities.
Vendor innovation is increasingly defined by interoperability, validated workflows, and flexible service models that lower barriers to clinical adoption
Key companies operating in the anatomic pathology space are concentrating on interoperability, assay validation, and service models that reduce adoption friction for clinical laboratories and hospitals. Vendors are investing in modular systems that allow buyers to scale functionality over time, combining hardware such as slide scanners with cloud-enabled image analysis and integrated laboratory information system connectors. In addition, reagent and consumable suppliers are differentiating by offering assay bundles and validated workflows that simplify accreditation and reduce the internal validation burden for pathology teams.
Strategic partnerships between technology developers, diagnostic laboratories, and academic centers are becoming more prominent, as they accelerate clinical validation and broaden use case evidence. Companies that provide robust post-deployment support, transparent validation data, and pathways for regulatory compliance tend to earn greater trust from institutional buyers. Moreover, those that enable instrument-agnostic assay implementation and offer flexible commercial terms-such as outcome-based service agreements or consumable-inclusive contracts-are achieving stronger engagement with high-volume diagnostic networks and research organizations. Ultimately, the vendors that balance technological innovation with pragmatic service and compliance offerings are best positioned to support the complex needs of modern anatomic pathology stakeholders.
Practical and strategic actions for leaders to strengthen diagnostic performance, supply resilience, workforce capability, and sustainable technology adoption
Industry leaders should prioritize strategic actions that strengthen diagnostic reliability, supply resilience, and clinical impact while managing total cost of ownership and regulatory risk. To begin, aligning procurement and clinical leadership around standardized validation protocols for digital and molecular assays will reduce duplicate efforts and accelerate deployment across multi-site networks. Next, diversifying suppliers for critical reagents and exploring regional distribution agreements can mitigate tariff-driven supply disruptions and shorten replenishment cycles. Concurrently, investing in workforce training and cross-disciplinary case review sessions will enhance diagnostic concordance and support the integration of novel biomarkers into routine practice.
Operationally, organizations should evaluate modular technology stacks that permit incremental capability upgrades without requiring full platform replacement, thereby preserving capital flexibility. Where feasible, negotiate service-level agreements that include remote diagnostics, preventive maintenance, and clear escalation pathways to maintain uptime for essential instruments. Finally, establish partnerships with academic centers and research institutes to co-develop validation datasets and share best practices, which can reduce time-to-clinical utility for emerging assays. Taken together, these actions will help leaders balance innovation with operational rigor and ensure sustained diagnostic performance in evolving clinical contexts.
An evidence-driven methodology combining clinical validation, stakeholder interviews, and technical literature to produce operationally relevant insights
The research approach for this analysis combined a comprehensive review of peer-reviewed literature, regulatory guidance, technical validation studies, and primary stakeholder interviews to ensure balanced, evidence-based conclusions. Clinical and laboratory informants were engaged to validate operational implications and to surface implementation challenges across diverse institutional settings. Technical sources were used to corroborate device capabilities and assay performance claims, while policy and supply chain references informed assessments of procurement and tariff-related impacts.
Analytical methods included cross-validation of qualitative insights with documented regulatory pathways and published technical evaluations, followed by synthesis into strategic implications relevant to hospitals, diagnostic laboratories, and research institutes. The methodology emphasized triangulation: where possible, findings from vendor documentation were compared with independent validation studies and frontline practitioner experience to highlight both promise and practical constraints. Throughout, efforts were made to ensure transparency in source attribution and reasoning, and to present recommendations that are operationally actionable within existing regulatory and clinical frameworks.
Strategic synthesis of technological, operational, and policy considerations to guide sustainable modernization of anatomic pathology services
In conclusion, anatomic pathology is transitioning toward integrated diagnostic paradigms that fuse digital imaging, immunohistochemistry, and molecular testing to deliver richer diagnostic context and more precise clinical guidance. These shifts require laboratories and hospital systems to reexamine procurement strategies, workforce development, and validation practices in order to realize the full clinical and operational benefits of new technologies. While tariff shifts and supply chain pressures introduce complexity, they also incentivize more robust sourcing strategies and partnerships that enhance long-term resiliency.
Moving forward, institutions that proactively harmonize workflows, invest in interoperable platforms, and foster collaborative validation with research partners will be better positioned to translate technical advances into measurable improvements in diagnostic accuracy and patient care. The path to modernization is pragmatic: prioritize validated, scalable solutions; maintain focus on compliance and service continuity; and invest in people and processes alongside technology to ensure sustainable returns on diagnostic innovation.
Please Note: PDF & Excel + Online Access - 1 Year
A comprehensive orientation to the evolving clinical, technological, and operational forces redefining anatomic pathology practice for decision-makers
Anatomic pathology stands at a crossroads of technological innovation, clinical demand, and operational transformation. This executive summary synthesizes the most salient developments shaping diagnostic practice, laboratory modernization, and research applications, drawing a line from laboratory bench processes through computational interpretation to clinical decision-making. It is intended to orient senior leaders, procurement teams, and clinical directors to practical implications and strategic opportunities that emerge as anatomic pathology adapts to evolving demands.
The following analysis emphasizes changes in diagnostic workflows, the integration of image analysis and molecular modalities, and the shifting relationships among providers, payers, and technology vendors. By emphasizing interoperability, regulatory alignment, and workforce dynamics, the narrative frames how institutions can translate technical advances into measurable improvements in diagnostic accuracy, turnaround times, and downstream patient management pathways. Alongside these themes, the summary highlights actionable considerations for capital planning, vendor selection, and internal capability building, providing a coherent foundation for strategic decision-making in the current clinical and commercial environment.
How converging advances in imaging, immunochemistry, and molecular diagnostics are reshaping diagnostic pathways, workflows, and laboratory partnerships
The anatomic pathology landscape is experiencing transformative shifts driven by digital enablement, expanding molecular diagnostics, and cross-disciplinary collaboration. Digital pathology platforms are moving beyond static image capture toward integrated systems that combine high-resolution slide scanners with advanced image analysis software, enabling pathologists to scale review workflows, support remote consultations, and standardize quantitation across cases. At the same time, immunohistochemistry remains fundamental, with monoclonal and polyclonal antibody reagent development improving specificity for biomarkers that inform therapeutic choices.
Concurrently, molecular pathology modalities such as fluorescence in situ hybridization, next-generation sequencing, and polymerase chain reaction are increasingly embedded into diagnostic algorithms, driving richer phenotypic and genotypic characterization of disease. Special staining techniques, including periodic acid–Schiff, silver, and trichrome stains, continue to provide critical morphological context that complements molecular readouts. These trends are occurring alongside workforce and workflow innovations, including centralized testing networks and partnerships between diagnostic laboratories and research institutes, which together are accelerating the translation of new assays into routine practice. As a result, institutions that can harmonize digital, immunohistochemical, and molecular domains are positioned to deliver more precise, reproducible, and clinically actionable pathology services.
The ripple effects of tariff policy shifts on supply stability, procurement strategies, and operational continuity in anatomic pathology settings
In 2025, changes to tariff policy in the United States have had a cumulative influence on supply chain dynamics and procurement decisions across anatomic pathology providers. Import tariffs and related customs adjustments have increased the cost sensitivity of capital equipment purchases such as slide scanners and ancillary hardware, while also affecting the landed cost of reagents and consumables that laboratories rely on for routine staining, immunohistochemistry, and molecular assays. These shifts have encouraged procurement teams to reevaluate sourcing strategies and to place greater emphasis on supplier diversification, local inventory buffering, and contractual protections against future tariff volatility.
Practically speaking, laboratories and research institutes have responded by negotiating longer-term supply contracts, seeking multi-source vendor relationships, and accelerating adoption of instrument-agnostic assays where possible. In parallel, some organizations have explored near-shoring or partnering with regional distributors to mitigate delivery lead times and customs complexity. Because equipment maintenance, validation, and regulatory compliance are critical, institutions must weigh the tradeoffs between short-term cost savings and long-term service reliability. Overall, tariff-related pressures have reinforced the importance of supply chain resilience, strategic stock management, and contractual clarity with vendors to sustain uninterrupted diagnostic operations and protect patient care continuity.
How multidimensional segmentation across test types, sample classes, applications, and end users informs targeted product development and deployment strategies
Segmentation insights reveal differentiated value drivers across test types, sample types, applications, and end users that collectively inform deployment and commercialization strategies. When considering test-type distinctions, digital pathology encompasses both image analysis software and slide scanners, each requiring distinct validation pathways and integration into laboratory information systems, whereas hematoxylin and eosin staining and special staining modalities such as periodic acid–Schiff, silver, and trichrome stains continue to underpin morphological assessment and support downstream ancillary testing. Immunohistochemistry divides into monoclonal antibody and polyclonal antibody reagents, with monoclonal formats often favored for standardized biomarker quantitation and polyclonal reagents retained for certain diagnostic contexts where broader antigen recognition is beneficial. Molecular pathology modalities span fluorescence in situ hybridization, next-generation sequencing, and polymerase chain reaction, collectively enabling diagnostic, prognostic, and predictive insights that complement histomorphology.
Turning to sample type, cytology samples, frozen sections, and tissue biopsy each pose differing pre-analytical and processing challenges that affect assay selection and workflow design; frozen sections demand rapid turnaround and robust intraoperative coordination, whereas tissue biopsy and cytology preparations enable a wider array of ancillary molecular and immunohistochemical testing. Application areas-genetic disorders, infectious diseases, and oncology-are further nuanced by sub-categories: genetic disorder testing differentiates between chromosomal and single-gene analyses; infectious disease testing separates bacterial from viral diagnostic approaches; and oncology applications prioritize organ-specific pathways such as breast, lung, and prostate cancer, which in turn shape marker panels and reflex testing strategies. Finally, end-user segmentation across diagnostic laboratories, hospitals, and research institutes underscores distinct procurement behaviors, validation requirements, and expectations for service levels. Diagnostic laboratories often prioritize throughput and assay standardization, hospitals emphasize integration with clinical pathways and turnaround, and research institutes value flexibility for novel assay development and exploratory biomarker evaluation. Together, these segmentation layers form a matrix that should guide product development, regulatory planning, and go-to-market tactics for stakeholders operating in anatomic pathology.
Regional adoption patterns and regulatory ecosystems that shape digital and molecular diagnostic deployment across the Americas, EMEA, and Asia-Pacific
Regional dynamics exert a strong influence on technology adoption, regulatory pathways, and partnership models across the anatomic pathology ecosystem. In the Americas, emphasis on consolidation among diagnostic providers and integrated delivery networks has driven investments in digital pathology and molecular testing infrastructure that supports centralized reference testing and telepathology services. This environment also fosters collaborations between hospitals and diagnostic laboratories to reduce turnaround times and support precision oncology programs.
In Europe, the Middle East & Africa, regulatory harmonization efforts, varying reimbursement landscapes, and a mix of centralized and decentralized laboratory networks create differentiated adoption patterns for advanced imaging and molecular assays. Regulatory alignment and cross-border collaborations are enabling broader deployment of validated digital workflows, while regional centers of excellence continue to drive training and best-practice dissemination. In the Asia-Pacific region, rapid capacity expansion, strong government-led initiatives to bolster diagnostic capability, and investments in local manufacturing and distribution networks are accelerating uptake of slide scanners, image analysis tools, and molecular platforms. Across all regions, local workforce capacity, reimbursement frameworks, and public health priorities modulate the pace and pattern of adoption, underlining the need for regionally tailored commercial and implementation strategies that respect regulatory and operational realities.
Vendor innovation is increasingly defined by interoperability, validated workflows, and flexible service models that lower barriers to clinical adoption
Key companies operating in the anatomic pathology space are concentrating on interoperability, assay validation, and service models that reduce adoption friction for clinical laboratories and hospitals. Vendors are investing in modular systems that allow buyers to scale functionality over time, combining hardware such as slide scanners with cloud-enabled image analysis and integrated laboratory information system connectors. In addition, reagent and consumable suppliers are differentiating by offering assay bundles and validated workflows that simplify accreditation and reduce the internal validation burden for pathology teams.
Strategic partnerships between technology developers, diagnostic laboratories, and academic centers are becoming more prominent, as they accelerate clinical validation and broaden use case evidence. Companies that provide robust post-deployment support, transparent validation data, and pathways for regulatory compliance tend to earn greater trust from institutional buyers. Moreover, those that enable instrument-agnostic assay implementation and offer flexible commercial terms-such as outcome-based service agreements or consumable-inclusive contracts-are achieving stronger engagement with high-volume diagnostic networks and research organizations. Ultimately, the vendors that balance technological innovation with pragmatic service and compliance offerings are best positioned to support the complex needs of modern anatomic pathology stakeholders.
Practical and strategic actions for leaders to strengthen diagnostic performance, supply resilience, workforce capability, and sustainable technology adoption
Industry leaders should prioritize strategic actions that strengthen diagnostic reliability, supply resilience, and clinical impact while managing total cost of ownership and regulatory risk. To begin, aligning procurement and clinical leadership around standardized validation protocols for digital and molecular assays will reduce duplicate efforts and accelerate deployment across multi-site networks. Next, diversifying suppliers for critical reagents and exploring regional distribution agreements can mitigate tariff-driven supply disruptions and shorten replenishment cycles. Concurrently, investing in workforce training and cross-disciplinary case review sessions will enhance diagnostic concordance and support the integration of novel biomarkers into routine practice.
Operationally, organizations should evaluate modular technology stacks that permit incremental capability upgrades without requiring full platform replacement, thereby preserving capital flexibility. Where feasible, negotiate service-level agreements that include remote diagnostics, preventive maintenance, and clear escalation pathways to maintain uptime for essential instruments. Finally, establish partnerships with academic centers and research institutes to co-develop validation datasets and share best practices, which can reduce time-to-clinical utility for emerging assays. Taken together, these actions will help leaders balance innovation with operational rigor and ensure sustained diagnostic performance in evolving clinical contexts.
An evidence-driven methodology combining clinical validation, stakeholder interviews, and technical literature to produce operationally relevant insights
The research approach for this analysis combined a comprehensive review of peer-reviewed literature, regulatory guidance, technical validation studies, and primary stakeholder interviews to ensure balanced, evidence-based conclusions. Clinical and laboratory informants were engaged to validate operational implications and to surface implementation challenges across diverse institutional settings. Technical sources were used to corroborate device capabilities and assay performance claims, while policy and supply chain references informed assessments of procurement and tariff-related impacts.
Analytical methods included cross-validation of qualitative insights with documented regulatory pathways and published technical evaluations, followed by synthesis into strategic implications relevant to hospitals, diagnostic laboratories, and research institutes. The methodology emphasized triangulation: where possible, findings from vendor documentation were compared with independent validation studies and frontline practitioner experience to highlight both promise and practical constraints. Throughout, efforts were made to ensure transparency in source attribution and reasoning, and to present recommendations that are operationally actionable within existing regulatory and clinical frameworks.
Strategic synthesis of technological, operational, and policy considerations to guide sustainable modernization of anatomic pathology services
In conclusion, anatomic pathology is transitioning toward integrated diagnostic paradigms that fuse digital imaging, immunohistochemistry, and molecular testing to deliver richer diagnostic context and more precise clinical guidance. These shifts require laboratories and hospital systems to reexamine procurement strategies, workforce development, and validation practices in order to realize the full clinical and operational benefits of new technologies. While tariff shifts and supply chain pressures introduce complexity, they also incentivize more robust sourcing strategies and partnerships that enhance long-term resiliency.
Moving forward, institutions that proactively harmonize workflows, invest in interoperable platforms, and foster collaborative validation with research partners will be better positioned to translate technical advances into measurable improvements in diagnostic accuracy and patient care. The path to modernization is pragmatic: prioritize validated, scalable solutions; maintain focus on compliance and service continuity; and invest in people and processes alongside technology to ensure sustainable returns on diagnostic innovation.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption of AI-driven digital pathology platforms for remote diagnostic collaboration
- 5.2. Development of multiplex immunohistochemistry assays for comprehensive tumor profiling
- 5.3. Emergence of liquid biopsy integration with histopathology workflows for early cancer detection
- 5.4. Regulatory approvals driving the commercialization of AI pathology tools for precision medicine
- 5.5. Standardization of digital slide scanning protocols to improve cross-institutional data compatibility
- 5.6. Implementation of cloud-based pathology information systems to streamline lab operations
- 5.7. Emerging trend of AI-enabled predictive biomarkers for personalized oncology treatment planning
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Anatomic Pathology Testing Market, by Test Type
- 8.1. Digital Pathology
- 8.1.1. Image Analysis Software
- 8.1.2. Slide Scanners
- 8.2. Hematoxylin And Eosin Staining
- 8.3. Immunohistochemistry
- 8.3.1. Monoclonal Antibody
- 8.3.2. Polyclonal Antibody
- 8.4. Molecular Pathology
- 8.4.1. Fluorescence In Situ Hybridization
- 8.4.2. Next Generation Sequencing
- 8.4.3. Polymerase Chain Reaction
- 8.5. Special Staining
- 8.5.1. Periodic Acid-Schiff Stain
- 8.5.2. Silver Stain
- 8.5.3. Trichrome Stain
- 9. Anatomic Pathology Testing Market, by Sample Type
- 9.1. Cytology Samples
- 9.2. Frozen Sections
- 9.3. Tissue Biopsy
- 10. Anatomic Pathology Testing Market, by Application
- 10.1. Genetic Disorders
- 10.1.1. Chromosomal Disorders
- 10.1.2. Single Gene Disorders
- 10.2. Infectious Diseases
- 10.2.1. Bacterial Infections
- 10.2.2. Viral Infections
- 10.3. Oncology
- 10.3.1. Breast Cancer
- 10.3.2. Lung Cancer
- 10.3.3. Prostate Cancer
- 11. Anatomic Pathology Testing Market, by End User
- 11.1. Diagnostic Laboratories
- 11.2. Hospitals
- 11.3. Research Institutes
- 12. Anatomic Pathology Testing Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Anatomic Pathology Testing Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Anatomic Pathology Testing Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. F. Hoffmann‑La Roche AG
- 15.3.2. Danaher Corporation
- 15.3.3. Thermo Fisher Scientific Inc.
- 15.3.4. Agilent Technologies Inc.
- 15.3.5. Abbott Laboratories
- 15.3.6. Hologic Inc.
- 15.3.7. Quest Diagnostics Incorporated
- 15.3.8. Laboratory Corporation of America Holdings
- 15.3.9. NeoGenomics Laboratories Inc.
- 15.3.10. BioGenex Laboratories Inc.
- 15.3.11. Sakura Finetek USA Inc.
- 15.3.12. PerkinElmer Inc.
- 15.3.13. Becton, Dickinson and Company
- 15.3.14. Merck KGaA
- 15.3.15. Bio SB Inc.
- 15.3.16. Philips Healthcare
- 15.3.17. Hamamatsu Photonics K.K.
- 15.3.18. Leica Biosystems
- 15.3.19. Qiagen N.V.
- 15.3.20. Eurofins Scientific SE
- 15.3.21. Synlab Holding GmbH
- 15.3.22. Sonic Healthcare Limited
- 15.3.23. Indica Labs LLC
- 15.3.24. Sysmex Corporation
- 15.3.25. Abcam plc
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
